Health
Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test – News-Medical.net
Aptamer Group, the developer of diagnostic and therapeutic Optimer™ reagents, today announced a commercial partnership with Mologic.
Aptamer Group, the developer of diagnostic and therapeutic Optimer™ reagents, today announced a commercial partnership with Mologic, a leading developer and manufacturer of lateral flow and rapid diagnostic tests.
The partnership will work towards CE marking of Aptamer Group’s AptaDx SARS-CoV-2 lateral flow rapid antigen test for professional use, to detect the SARS-CoV-2 spike protein antigen in anterior nasal swabs. Initial test analysis with laboratory samples has demonstrated excellent sensitivity…
-
General14 hours agoMan dies in daylight shooting in Sydney’s north-west
-
Noosa News23 hours agoCouncil steps up staff protection after surge in abuse
-
Noosa News18 hours agoResident rushed to hospital with multiple burns as house engulfed in flames in Woodridge
-
Noosa News16 hours agoWhy the Brisbane City Hall clock has fallen silent